Back

Leukemic Cells Manipulate MSCs Bioelectrical Signals to Reshape the Bone Marrow Niche

Borella, G.; Benetton, M.; Da Ros, A.; Longo, G.; Borile, G.; Cani, A.; Lopez-Pigozzi, D.; Bortolozzi, M.; Bresolin, S.; Tregnago, C.; Locatelli, F.; Pigazzi, M.

2025-03-13 cancer biology
10.1101/2025.03.10.642319 bioRxiv
Show abstract

Mesenchymal stromal cells (MSCs) are key components of the tumor microenvironment (TME), influencing leukemia progression through poorly understood mechanisms. We investigated the bioelectrical properties of MSCs derived from pediatric AML patients (AML-MSCs) and identified a significant depolarization of their resting membrane potential (Vmem, -14.7mV) compared to healthy MSCs (h-MSCs, -28.5mV), accompanied by downregulation of CaV1.2 L-type calcium channel expression. AML-MSCs displayed increased spontaneous calcium oscillations, suggesting altered ion homeostasis. Notably, h-MSCs exposed to AML blasts underwent a similar Vmem depolarization (-11.8mV) and CaV1.2 downregulation, indicating that leukemic cells actively reprogram MSCs. Functionally, Vmem depolarization in h-MSCs promoted a pro-leukemic phenotype, whereas hyperpolarization of AML-MSCs restored a normal behavior. CaV1.2 over-expression by lentiviral vectors in AML-MSCs shifted Vmem toward hyperpolarization and partially reversed their leukemia-supportive properties, in part through CaV1.2 transfer via tunneling nanotubes. These findings reveal that AML blasts impose a bioelectrical signature on MSCs, modulating ion channel activity to sustain a leukemic niche. Targeting this electrical reprogramming through CaV1.2 restoration represents a potential strategy to re-establish homeostasis in the bone marrow microenvironment.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

1
Nature Communications
5641 papers in training set
Top 15%
12.0%
2
Cell Death & Disease
126 papers in training set
Top 0.2%
6.8%
3
Leukemia
42 papers in training set
Top 0.2%
6.8%
4
Oncogenesis
12 papers in training set
Top 0.1%
4.4%
5
Cancers
213 papers in training set
Top 1%
4.4%
6
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.1%
4.1%
7
Scientific Reports
3612 papers in training set
Top 33%
3.2%
8
eLife
5828 papers in training set
Top 35%
3.2%
9
iScience
1154 papers in training set
Top 10%
2.5%
10
Biomedicine & Pharmacotherapy
42 papers in training set
Top 0.3%
2.5%
11
Stem Cell Reports
130 papers in training set
Top 0.9%
2.4%
50% of probability mass above
12
Blood Advances
62 papers in training set
Top 0.6%
2.1%
13
EMBO Reports
263 papers in training set
Top 3%
1.9%
14
Experimental Hematology
11 papers in training set
Top 0.1%
1.7%
15
Stem Cells
31 papers in training set
Top 0.4%
1.7%
16
Haematologica
25 papers in training set
Top 0.4%
1.7%
17
Communications Biology
993 papers in training set
Top 14%
1.7%
18
Journal of Hematology & Oncology
10 papers in training set
Top 0.2%
1.4%
19
Stem Cell Research & Therapy
30 papers in training set
Top 0.4%
1.3%
20
Blood
74 papers in training set
Top 0.9%
1.3%
21
Cells
249 papers in training set
Top 4%
1.3%
22
EMBO Molecular Medicine
95 papers in training set
Top 2%
1.1%
23
Science Advances
1243 papers in training set
Top 24%
1.1%
24
Experimental Cell Research
28 papers in training set
Top 0.4%
1.1%
25
Journal of Clinical Investigation
179 papers in training set
Top 4%
1.1%
26
Cell Reports
1498 papers in training set
Top 23%
1.1%
27
npj Precision Oncology
53 papers in training set
Top 1%
1.0%
28
Advanced Science
286 papers in training set
Top 8%
1.0%
29
Biomaterials
84 papers in training set
Top 1%
1.0%
30
Cell Death & Differentiation
48 papers in training set
Top 1%
0.9%